Cor Vasa 2026, 68(1):61-65

(Acoramidis: another treatment option for transthyretin cardiac amyloidosis)

Tomáš Paleček
Centrum pro choroby myokardu a perikardu, II. interní klinika kardiologie a angiologie, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze, Praha, Česká republika

Transthyretin amyloidosis (ATTR) of the heart is a progressive and ultimately fatal disease characterized by the deposition of insoluble amyloid fibrils, derived from the misfolded protein transthyretin (TTR), in the myocardium. In the Czech Republic, wild-type ATTR cardiomyopathy (ATTRwt) dominates, typically affecting individuals older than 65 years. The hereditary form of ATTR (ATTRv) is probably rare in our country. In the last 15 years, there has been a significant development in the field of specific, disease-modifying treatment of ATTR cardiomyopathy. This therapy focuses either on influencing TTR synthesis in the liver (suppressors of TTR formation), on stabilizing TTR tetramers in serum or, so far within the framework of research, on removing already formed amyloid fibrils. This overview presents a new oral TTR stabilizer acoramidis, the administration of which leads to almost complete stabilization of serum TTR levels. The clinical effect of treating ATTR cardiomyopathy with acoramidis, associated with a significant impact on morbidity and mortality of affected individuals, was demonstrated within the primary endpoint of the ATTRibute-CM trial. Since February 2025, acoramidis (Beyonttra) has been registered for the treatment of ATTR of the heart in adult patients in the European Union.

Keywords: Amyloidosis, Heart failure, Transthyretin

Received: December 3, 2025; Revised: December 3, 2025; Accepted: December 7, 2025; Prepublished online: June 2, 2012; Published: March 15, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Paleček T. (Acoramidis: another treatment option for transthyretin cardiac amyloidosis). Cor Vasa. 2026;68(1):61-65.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Fontana M, Berk JL, Drachman B, et al. Changing Treatment Landscape in Transthyretin Cardiac Amyloidosis. Circ Heart Fail 2025;18: e012112.
    2. Muchtar E, Dispenzieri A, Gertz MA, et al. Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. Mayo Clin Proc 2021;96:1546-1577.
    3. Fontana M, Ioannou A, Cuddy S, et al. The Last Decade in Cardiac Amyloidosis: Advances in Understanding Pathophysiology, Diagnosis and Quantification, Prognosis, Treatment Strategies, and Monitoring Response. JACC Cardiovasc Imaging 2025;18:478-499.
    4. Kubánek M. Transthyretinová kardiomyopatie-přehled problematiky v roce 2025. Vnitř Lék 2025;71:289-294.
    5. Garcia-Pavia P, Gonzalez-Lopez E, Anderson LJ, et al. Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association. Eur Heart J 2026;47:22-36.
    6. Gonzalez-Lopez E, Maurer MS, Garcia-Pavia P. Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine. Eur Heart J 2025;46:999-1013.
    7. Paleček T, Krejčí J. Studie ATTR-ACT: přelom v léčbě transthyretinové srdeční amyloidózy. Interv Akut Kardiol 2019;18:45-48.
    8. Penchala SC, Connelly S, Wang Y, et al. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc Natl Acad Sci US 2013;110: 9992-9997.
    9. Miller M, Pal A, Albusairi W, et al. Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis. J Med Chem 2018;61:7862-7876.
    10. Nelson LT, Paxman RJ, Xu J, et al. Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma. Amyloid 2021;28:24-29.
    11. Greve AM, Christoffersen M, Frikke-Schmidt R, et al. Association of Low Plasma Transthyretin Concentration With Risk of Heart Failure in the General Population. JAMA Cardiol 2021;6:258-266.
    12. Hanson JLS, Arvanitis M, Koch CM, et al. Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin. Circ Heart Fail 2018;11: e004000.
    13. Minervini A, Barge-Caballero G, López-López A, et al. Transthyretin serum levels and clinical outcomes in patients with transthyretin amyloid cardiomyopathy. Eur J Intern Med 2025;142:106350.
    14. Fox JC, Hellawell JL, Rao S, et al. First-in-Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult Volunteers. Pharmacol Drug Dev 2020;9:115-129.
    15. udge DP, Heitner SB, Falk RH, et al. Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol 2019;74: 285-295.
    16. Gillmore JD, Judge DP, Cappelli F, et al. Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy. N Engl J Med 2024;390: 132-142.
    17. Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med 2018;379:1007-1016.

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content